Protocols

First-line therapy

• International PTLD-1 Trial

  Treatment of patients with Post-Transplant Lymphoproliferative Disorder (PTLD) with a sequential treatment consisting of 4 courses of the anti-CD20 antibody Rituximab followed by 4 cycles of CHOP-21 chemotherapy

  
  
• International PTLD-1 Trial, 3rd amendment

  Treatment of patients with Post-Transplant Lymphoproliferative Disorder (PTLD) with a sequential treatment consisting of 4 courses of the anti-CD20 antibody Rituximab followed by 4 further courses of Rituximab monotherapy in favourite risk patients or by 4 cycles of R-CHOP-21 chemotherapy

  
  
  For further information please contact us.